TORONTO — The Ontario government unveiled the next phase of its life sciences strategy, aimed at driving innovation, boosting investments and enhancing research to further solidify the province as a global leader in biomanufacturing and health sciences. This includes a $146 million investment to help fuel the sector’s growth. “As we rebuild Ontario’s economy, the life sciences sector will play …
MODERNA AND NOVOCOL PHARMA ANNOUNCE FILL-FINISH AGREEMENT FOR CANADIAN-MADE MRNA VACCINES
Vaccines manufactured at Moderna’s state-of-the-art Canadian mRNA facility to be prepared and packaged at Novocol’s Ontario-based facility Fill-finish agreement will secure domestic end-to-end vaccine production and ensures rapid response capabilities for future pandemic readiness for Canadians TORONTO-Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a long-term agreement with Ontario-based Novocol Pharma, a leading …